Company: MDCXW
Filing Date: 2025-05-30
Form Type: 424B3
Source: 0001062993-25-010580
Chunk: 195

Company: Medicus Pharma Ltd.
Filing Date: 2025-05-30
Form: 424B3
Chunk 195
---
 gross proceeds from the disposition of, our common shares paid to a foreign financial institution or non-financial foreign entity. Foreign financial institutions located in jurisdictions that have an intergovernmental agreement with the United States governing FATCA may be subject to different rules.

<div align='center'>- 131 -</div>

Withholding under FATCA currently applies to dividends paid in respect of our common shares. Proposed Treasury Regulations, the preamble to which state that they can be relied upon until final Treasury Regulations are issued, exempt from FATCA withholding gross proceeds from the dispositions of stock. To prevent withholding on dividends, Non-U.S. Holders may be required to provide the Company (or its withholding agents) with applicable tax forms or other information. Non-U.S. Holders are urged to consult with their own tax advisors regarding the effect, if any, of FATCA to them based on their particular circumstances.

<div align='center'>STANDBY EQUITY PURCHASE AGREEMENT</div>

On February 10, 2025, we entered into the SEPA with the Selling Shareholder. Pursuant to the SEPA, we have the right to sell to the Selling Shareholder up to $15,000,000 of our common shares, subject to certain limitations and conditions set forth in the SEPA, from time to time during the term of the SEPA. Sales of common shares pursuant to the SEPA, and the timing of any sales, are at our option, and we are under no obligation to sell any securities to the Selling Shareholder under the SEPA. In accordance with our obligations under the SEPA, we have filed with the SEC the registration statement of which this prospectus forms a part to register under the Securities Act the resale by the Selling Shareholder of up to 3,710,000 of our common shares, consisting of 105,840 Commitment Shares that we issued to the Selling Shareholder as payment of a commitment fee for its commitment to purchase common shares at our election under the SEPA, and approximately 3,604,160 common shares that we may elect, in our sole discretion, to issue and sell to the Selling Shareholder, from time to time under the SEPA.

We do not have the right to commence any sales of our common shares to the Selling Shareholder under the SEPA until the date on which all of the conditions to the Selling Shareholder's purchase obligation set forth in the SEPA have been satisfied, including that the registration statement of which this prospectus forms a